Amylin Pharmaceuticals will present fresh data on diabetes drugs including Byetta and Symli, not to mention pipeline diabetes and obesity drug candidates. The data will be revealed at the annual Scientific Sessions put on by the American Diabetes Association.
Health care professionals involved in diabetes research and treatment come from all over the world to the ADA meetings. Amylin has gathered information resources and will present their findings orally and using posters. Amylin will present two symposia focused on multi-hormonal treatment of diabetes and obesity .
The president and CEO of Amylin, Daniel Bradbury, was reported as commenting: “We are excited to demonstrate advancement in our diabetes and obesity pipeline programs at this year’s ADA, particularly with updated data related to the once-weekly formulation of exenatide and the combination therapy program for obesity. At Amylin, we continually strive toward our mission of Challenging Science and Changing Lives. By challenging science we question conventional thinking, and open the door for truly innovative approaches for developing novel, life-changing therapies. This unique approach, paired with our deep expertise in peptide hormones and broad experience in diabetes markets, has allowed us to continue developing important medicines with life-changing therapeutic potential for patients.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…